Clinical Trials
83 trialsPSMA SRT
Jonsson Comprehensive Cancer Center
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
Mayo Clinic
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Peking Union Medical College Hospital
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
Mayo Clinic
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
68Ga-PSMA PET/CT for Ra223 Assessment
Chang Gung Memorial Hospital
Re-treatment 225Ac-J591 for mCRPC
Weill Medical College of Cornell University
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
HEATWAVE
Jonsson Comprehensive Cancer Center
PPPIMS
Royal Marsden NHS Foundation Trust
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Mayo Clinic
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Emory University
GaPSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
BASKET PSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
Mayo Clinic
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
University of Iowa
High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Universitaire Ziekenhuizen KU Leuven
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
The First Affiliated Hospital of Anhui Medical University
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Stanford University
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Stanford University
68Ga-PSMA PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma
Mayo Clinic
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of Michigan
68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer
First Affiliated Hospital of Fujian Medical University
68 Ga-PSMA for High Risk Prostate Cancer
The Methodist Hospital Research Institute
PET/MRI in Patients With Suspected Prostate Cancer
Medical University of Vienna
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
City of Hope Medical Center
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center